Zymeworks Current Ratio 2016-2022 | ZYME

Zymeworks current ratio from 2016 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Zymeworks Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $0.26B $0.08B 3.29
2022-03-31 $0.32B $0.08B 4.05
2021-12-31 $0.29B $0.07B 4.01
2021-09-30 $0.34B $0.08B 4.47
2021-06-30 $0.39B $0.08B 4.73
2021-03-31 $0.43B $0.07B 6.16
2020-12-31 $0.46B $0.09B 5.31
2020-09-30 $0.49B $0.10B 5.03
2020-06-30 $0.47B $0.07B 6.48
2020-03-31 $0.51B $0.07B 6.92
2019-12-31 $0.31B $0.08B 3.78
2019-09-30 $0.35B $0.05B 6.81
2019-06-30 $0.37B $0.04B 9.07
2019-03-31 $0.19B $0.03B 6.76
2018-12-31 $0.20B $0.03B 6.82
2018-09-30 $0.15B $0.02B 6.42
2018-06-30 $0.17B $0.02B 7.26
2018-03-31 $0.07B $0.02B 4.09
2017-12-31 $0.09B $0.02B 6.30
2017-09-30 $0.05B $0.01B 4.57
2017-06-30 $0.07B $0.01B 5.60
2017-03-31 $0.03B $0.02B 1.57
2016-12-31 $0.05B $0.02B 2.81
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.02B $0.01B 3.64
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.519B $0.412B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.172B 8.84
GSK (GSK) United Kingdom $75.535B 9.47
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.564B 19.57
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.289B 0.00
Biohaven (BHVN) United States $0.959B 0.00
Emergent Biosolutions (EBS) United States $0.444B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.111B 0.00
SQZ Biotechnologies (SQZ) United States $0.019B 0.00
Gelesis Holdings (GLS) United States $0.013B 0.00